Expanding access to long-acting HIV medication
Part of Infections clinical trials.
This study tests whether a pharmacist can safely give long-acting HIV medications every 4 or 8 weeks. It aims to help more people with HIV get this treatment easily.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have tested positive for HIV
- You must already be taking the long-acting HIV injection every 4 or 8 weeks
- You must have received at least two doses of this injection
- Your last HIV viral load (amount of virus in your blood) must be under 50 copies/mL
- You must not have resistance to cabotegravir or rilpivirine
- You must agree not to change your HIV medication during the 48-week study
- You must plan to stay in the state during the study
- If you can get pregnant, you must agree to use effective birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new ultra-long-acting injectable combination of cabotegravir and rilpivirine for people with HIV who already have the virus under control. It aims to see if these shots can keep the virus suppressed with fewer doses.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This study tests a nurse-led program that offers a long-acting injectable medication (cabotegravir) to prevent HIV. The injection is given every two months, and the program aims to make it easier to access this prevention option at your local health center.
This trial tests whether switching from daily HIV pills to a long-acting injectable combination (cabotegravir and rilpivirine) is safe and effective for people whose HIV is well controlled. Instead of taking pills every day, you would receive a shot every month or two, which may be more convenient.
This trial provides cabotegravir, a long-acting injectable HIV medicine, for people who cannot take or absorb oral HIV medications. It is for those who have no other effective treatment options.
This study looks back at medical records of people with HIV-1 who have received a long-acting injectable treatment called cabotegravir plus rilpivirine. It aims to see how well this treatment works for people with a specific HIV subtype (A6).
Hear when a new HIV I Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.